Michael Lassmann

List of Publications by Year
in descending order

161 papers	9,787 citations	34105 52 h-index	39675 94 g-index
183 all docs	183 docs citations	183 times ranked	6635 citing authors

#	Article	IF	Citations
1	Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1941-1959.	6.4	593
2	EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 855-897.	6.4	467
3	⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	5.0	432
4	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 926-932.	3.6	405
5	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
6	MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ¹⁷⁷Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 151-162.	5.0	235
7	EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1238-1250.	6.4	217
8	EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1039-1047.	6.4	212
9	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine, 2006, 47, 648-54.	5.0	209
10	EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1405-1412.	6.4	204
11	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	5.0	201
12	Spatial dose mapping for individualizing radioiodine treatment. Journal of Nuclear Medicine, 2007, 48, 2-4.	5.0	200
13	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1976-1988.	6.4	179
14	EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2218-2228.	6.4	174
15	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clinical Nuclear Medicine, 2016, 41, 515-521.	1.3	165
16	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. Theranostics, 2015, 5, 618-630.	10.0	162
17	The new EANM paediatric dosage card. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 796-798.	6.4	160
18	EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 192-200.	6.4	156

#	Article	IF	Citations
19	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	3.1	154
20	A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1202-1222.	6.4	131
21	Dose Mapping After Endoradiotherapy with ¹⁷⁷Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. Journal of Nuclear Medicine, 2018, 59, 75-81.	5.0	125
22	Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1036-1041.	6.4	124
23	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	5.0	122
24	In Vivo Formation of Î³-H2AX and 53BP1 DNA Repair Foci in Blood Cells After Radioiodine Therapy of Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2010, 51, 1318-1325.	5.0	117
25	EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1126-1134.	6.4	117
26	Sentinel node in breast cancer procedural guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2154-2159.	6.4	114
27	EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1750-1766.	6.4	110
28	Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2009, 16, 3190-3210.	1.5	108
29	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	5.0	108
30	The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide Therapy. Zeitschrift Fur Medizinische Physik, 2006, 16, 47-59.	1.5	107
31	Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocrine-Related Cancer, 2010, 17, R161-R172.	3.1	103
32	Dosimetry of 223Ra-chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 207-212.	6.4	101
33	Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1371-1377.	6.4	95
34	[¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017, 7, 2350-2362.	10.0	84
35	Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?. Journal of Nuclear Medicine, 2017, 58, 97S-103S.	5.0	83
36	Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics, 2017, 7, 1489-1498.	10.0	82

#	Article	IF	Citations
37	Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4171-4179.	3.6	78
38	The new EANM paediatric dosage card: additional notes with respect to F-18. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1666-1668.	6.4	76
39	EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 616-622.	6.4	74
40	Molecular radiotherapy: The NUKFIT software for calculating the timeâ€integrated activity coefficient. Medical Physics, 2013, 40, 102504.	3.0	73
41	Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 896-903.	6.4	72
42	Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiation Oncology, 2012, 7, 99.	2.7	71
43	Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer, 2009, 16, 1283-1289.	3.1	70
44	The Use of Three-Dimensional Ultrasound for Thyroid Volumetry. Thyroid, 2001, 11, 569-574.	4.5	68
45	Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1915-1936.	6.4	66
46	Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine, 2018, 59, 909-914.	5.0	65
47	Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine, 2004, 45, 619-25.	5.0	63
48	EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 67-72.	6.4	62
49	Pediatric Radiopharmaceutical Administration: Harmonization of the 2007 EANM Paediatric Dosage Card (Version 1.5.2008) and the 2010 North American Consensus guideline. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1636-1636.	6.4	61
50	Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine â€“ a review. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2269-2281.	6.4	58
51	Radioiodine for remnant ablation and therapy of metastatic disease. Nature Reviews Endocrinology, 2011, 7, 589-595.	9.6	56
52	SNMMI and EANM Practice Guideline for Meckel Diverticulum Scintigraphy 2.0. Journal of Nuclear Medicine Technology, 2014, 42, 163-169.	0.8	51
53	Characterization of Noise and Resolution for Quantitative ¹⁷⁷Lu SPECT/CT with xSPECT Quant. Journal of Nuclear Medicine, 2019, 60, 50-59.	5.0	51
54	DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. Journal of Nuclear Medicine, 2016, 57, 173-179.	5.0	49

#	Article	IF	Citations
55	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1783-1786.	6.4	48
56	Calibration of the Î³-H2AX DNA Double Strand Break Focus Assay for Internal Radiation Exposure of Blood Lymphocytes. PLoS ONE, 2015, 10, e0123174.	2.5	47
57	ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. Annals of the ICRP, 2019, 48, 5-95.	3.8	45
58	The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 673-680.	6.4	44
59	Treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik, 2013, 23, 262-269.	1.5	44
60	EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours. EJNMMI Physics, 2020, 7, 15.	2.7	44
61	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
62	The NUKDOS software for treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik, 2015, 25, 264-274.	1.5	41
63	Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology. Journal of Nuclear Medicine, 2016, 57, 1998-2005.	5.0	40
64	Clinical radionuclide therapy dosimetry: the quest for the â€œHoly Grayâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1699-1700.	6.4	39
65	The Relevance of Dosimetry in Precision Medicine. Journal of Nuclear Medicine, 2018, 59, 1494-1499.	5.0	39
66	The new EANM paediatric dosage card. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1748-1748.	6.4	38
67	DNA damage in blood lymphocytes in patients after 177Lu peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1739-1749.	6.4	38
68	Optimizing Image Quantification for ¹⁷⁷Lu SPECT/CT Based on a 3D Printed 2-Compartment Kidney Phantom. Journal of Nuclear Medicine, 2018, 59, 616-624.	5.0	38
69	Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3640-3645.	3.6	38
70	Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. Current Radiopharmaceuticals, 2013, 6, 20-27.	0.8	36
71	Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT. Physics in Medicine and Biology, 2015, 60, 1945-1964.	3.0	36
72	Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 343-346.	6.4	35

#	Article	IF	Citations
73	Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study. Zeitschrift Fur Medizinische Physik, 2017, 27, 98-112.	1.5	35
74	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 152-154.	6.4	34
75	A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI Physics, 2021, 8, 55.	2.7	34
76	Therapy of ankylosing spondylitis with 224Ra-radium chloride: dosimetry and risk considerations. Radiation and Environmental Biophysics, 2002, 41, 173-178.	1.4	33
77	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 1â€"Statement of the Issue and a Review of Available Resources. Journal of Nuclear Medicine, 2015, 56, 646-651.	5.0	32
78	Facing the Nuclear Threat: Thyroid Blocking Revisited. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3511-3516.	3.6	31
79	DNA damage in leukocytes after internal ex-vivo irradiation of blood with the Î±-emitter Ra-223. Scientific Reports, 2018, 8, 2286.	3.3	29
80	Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?. PLoS ONE, 2013, 8, e71729.	2.5	28
81	Nanostructure of Clustered DNA Damage in Leukocytes after In-Solution Irradiation with the Alpha Emitter Ra-223. Cancers, 2019, 11, 1877.	3.7	27
82	Dosimetry prior to I-131-therapy of benign thyroid disease. Zeitschrift Fur Medizinische Physik, 2011, 21, 250-257.	1.5	26
83	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2â€"Current Standards and the Path Toward Global Standardization. Journal of Nuclear Medicine, 2016, 57, 1148-1157.	5.0	26
84	Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nuclear Medicine and Biology, 2018, 61, 36-44.	0.6	26
85	Track Structures and Dose Distributions from Decays of131I and125I in and around Water Spheres Simulating Micrometastases of Differentiated Thyroid Cancer. Radiation Research, 2001, 156, 419-429.	1.5	25
86	What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy. Journal of Nuclear Medicine, 2020, 61, 1178-1186.	5.0	25
87	Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection. Annals of the ICRP, 2018, 47, 187-195.	3.8	24
88	International Guidelines for Pediatric Radiopharmaceutical Administered Activities. Journal of Nuclear Medicine, 2014, 55, 869-870.	5.0	23
89	EANM position paper on the role of radiobiology in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3365-3377.	6.4	23
90	Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project. EJNMMI Physics, 2020, 7, 61.	2.7	23

#	Article	IF	Citations
91	Radioiodine (131 I) treatment of hyperthyroidism: radiation protection and quality assurance. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 683-685.	6.4	21
92	A Novel Thyroid Phantom for Ultrasound Volumetry: Determination of Intraobserver and Interobserver Variability. Thyroid, 2006, 16, 41-46.	4.5	21
93	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of ParkinsonÃ¢â‚¬â„¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 213.	3.4	21
94	131I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin - NuclearMedicine, 2011, 50, 93-99.	0.7	20
95	Nuclear medicine dosimetry: Quantitative imaging and dose calculations. Zeitschrift Fur Medizinische Physik, 2011, 21, 246-247.	1.5	19
96	Quantification of fat fraction in lumbar vertebrae: correlation with age and implications for bone marrow dosimetry in molecular radiotherapy. Physics in Medicine and Biology, 2018, 63, 025029.	3.0	19
97	Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals. EJNMMI Physics, 2018, 5, 17.	2.7	19
98	Curriculum for education and training of Medical Physicists in Nuclear Medicine. Physica Medica, 2013, 29, 139-162.	0.7	17
99	Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1971-1975.	6.4	17
100	Human Biodistribution and Radiation Dosimetry of ¹⁸F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. Journal of Nuclear Medicine, 2017, 58, 374-378.	5.0	17
101	Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World Journal of Radiology, 2014, 6, 480.	1.1	17
102	Dosimetry of [68Ga]-labeled compounds. Applied Radiation and Isotopes, 2013, 76, 70-74.	1.5	16
103	The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Physics in Medicine and Biology, 2014, 59, 2353-2368.	3.0	16
104	Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. Journal of Nuclear Medicine, 2014, 55, 1215-1216.	5.0	16
105	The â€œreset buttonâ€•revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 915-917.	6.4	16
106	The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget, 0, 7, 41233-41241.	1.8	16
107	A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. Medical Physics, 2013, 40, 082502.	3.0	15
108	177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Research, 2016, 6, 50.	2.5	15

#	Article	IF	Citations
109	Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224. EJNMMI Research, 2018, 8, 77.	2.5	14
110	Radiation Dosimetry Aspects of ¹⁷⁷Lu. Current Radiopharmaceuticals, 2015, 8, 139-144.	0.8	14
111	DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1723-1732.	6.4	13
112	Paediatric nuclear medicine practice: an international survey by the IAEA. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1552-1563.	6.4	12
113	Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine, 2005, 46, 899.	5.0	12
114	Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC. Nuklearmedizin - NuclearMedicine, 2017, 56, 219-224.	0.7	11
115	In Vivo Biokinetics of ¹⁷⁷Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry. Contrast Media and Molecular Imaging, 2019, 2019, 1-7.	0.8	11
116	Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2036-2039.	6.4	10
117	Biting the magic bullet: celebrating a decade of the EANM Dosimetry Committee. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1-3.	6.4	9
118	SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors. Clinical Nuclear Medicine, 2015, 40, e271-e277.	1.3	9
119	I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an â€œinconvenientâ€•truth?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2247-2249.	6.4	9
120	DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [68Ga]Ga-PSMA I&T. Cancers, 2020, 12, 388.	3.7	9
121	Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity-Concentration Measurements. Journal of Nuclear Medicine, 2020, 61, 1028-1029.	5.0	9
122	Quantitative imaging for clinical dosimetry. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 467-471.	1.6	8
123	Self-irradiation of the blood from selected nuclides in nuclear medicine. Physics in Medicine and Biology, 2014, 59, 1515-1531.	3.0	8
124	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 862-862.	5.0	8
125	¹³¹I activity quantification of gamma camera planar images. Physics in Medicine and Biology, 2017, 62, 909-926.	3.0	7
126	The effect of modern PET technology and techniques on the EANM paediatric dosage card. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1964-1969.	6.4	7

#	Article	IF	Citations
127	Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH. Journal of Nuclear Medicine, 2005, 46, 900-1; author reply 901.	5.0	7
128	Dosimetry for Radiopharmaceutical Therapy: The European Perspective. Journal of Nuclear Medicine, 2021, 62, 73S-79S.	5.0	7
129	Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 548-549.	6.4	6
130	Biokinetics, dosimetry, and radiation risk in infants after 99mTc-MAG3 scans. EJNMMI Research, 2018, 8, 10.	2.5	6
131	Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 278-86.	1.0	6
132	The IAEA Radiotracer Biodistribution Template â€“ A community resource for supporting the standardization and reporting of radionuclide pre-dosimetry data. Physica Medica, 2017, 44, 83-85.	0.7	5
133	Introduction; 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 45-46.	1.0	4
134	Dosimetry is Alive and Well. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 593-595.	1.0	4
135	The absorbed dose to blood from blood-borne activity. Physics in Medicine and Biology, 2015, 60, 741-753.	3.0	4
136	Standardization of administered activities in paediatric nuclear medicine: the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2275-2278.	6.4	4
137	Developing and Implementing an Imaging Optimization Study in Pediatric Nuclear Medicine: Experience and Recommendations from an IAEA-Coordinated Research Project. Journal of Nuclear Medicine, 2021, 62, 570-576.	5.0	4
138	Dose optimization in nuclear medicine. Clinical and Translational Imaging, 2016, 4, 3-4.	2.1	3
139	Dose optimization in pediatric nuclear medicine. Clinical and Translational Imaging, 2016, 4, 5-11.	2.1	3
140	Dose optimization in nuclear medicine therapy of benign and malignant thyroid diseases. Clinical and Translational Imaging, 2016, 4, 31-40.	2.1	3
141	A perspective on post-Chernobyl radioablation in young females. Journal of Nuclear Medicine, 2006, 47, 1563-4.	5.0	3
142	Repair of Î±-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with 223Ra. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3981-3988.	6.4	3
143	18F-FDG PET/CT scans for children and adolescents. Lancet Oncology, The, 2014, 15, e243-e244.	10.7	2
144	Quantification of the trabecular bone volume fraction for bone marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/)CT. Physics in Medicine and Biology, 2019, 64, 205014.	3.0	2

#	Article	IF	Citations
145	Developing and implementing a multi-modality imaging optimization study in paediatric radiology: Experience and recommendations from an IAEA coordinated research project. Physica Medica, 2021, 82, 255-265.	0.7	2
146	Modelling SPECT auto-contouring acquisitions for 177Lu & 131I molecular radiotherapy using new developments in Geant4/GATE. Physica Medica, 2022, 96, 101-113.	0.7	2
147	mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure. International Journal of Radiation Biology, 2022, 98, 900-912.	1.8	2
148	Monte Carlo Methods in Nuclear Medicine. Medical Radiology, 2012, , 759-768.	0.1	1
149	Standardization of pediatric nuclear medicine administered radiopharmaceutical activities: the SNMMI/EANM Joint Working Group. Clinical and Translational Imaging, 2016, 4, 203-209.	2.1	1
150	Internal Dosimetry: Principles and Applications to NET. , 2017, , 201-217.		1
151	Dosimetric Approaches: Current Concepts. , 2018, , 137-145.		1
152	Radioiodine dosimetry in advanced thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 227-228.	0.7	1
153	Toward a Patient-Specific Traceable Quantification of SPECT/CT-Based Radiopharmaceutical Distributions. Journal of Nuclear Medicine, 2022, 63, 1108-1116.	5.0	1
154	Quantification of the volume fraction of fat, water and bone mineral in spongiosa for red marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/)CT. Zeitschrift Fur Medizinische Physik, 2022, 32, 428-437.	1.5	1
155	EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 645-648.	6.4	0
156	EANM perspective. Radiation Protection Dosimetry, 2013, 153, 166-169.	0.8	0
157	Radio-iodine treatment of hyperthyroidism. , 2011, , 481-484.		0
158	Radiation Safety and Dosimetry. , 2016, , 103-111.		0
159	Nuklearmedizinische Therapie. , 2018, , 377-386.		0
160	GATE/Geant4-based dosimetry for ex vivo in solution irradiation of blood with radionuclides. Zeitschrift Fur Medizinische Physik, 2022, , .	1.5	0
161	Is a single late SPECT/CT based kidney 177Lu-dosimetry superior to hybrid dosimetry with sequential multiple time-point whole-body planar scans in combination with an early SPECT/CT?. Physica Medica, 2022, 100, 39-50.	0.7	0